Solid Tumors
Conditions
Keywords
solid tumors, balugrastim
Brief summary
The primary objective of this study is to find the optimal dose of balugrastim by characterizing its pharmacokinetics (PK), and by comparing the pharmacodynamics (PD) of balugrastim to filgrastim in children receiving chemotherapy.
Interventions
DRUGBalugrastim
Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
DRUGFilgrastim
Filgrastim 5 μg/kg
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Histological or cytologically-confirmed solid tumor in a patient for whom the study chemotherapy regimen \[Vincristine plus ifosfamide plus doxorubicin plus etoposide (VIDE), Vincristine plus doxorubicin plus cyclophosphamide alternating with ifosfamide plus etoposide (VDC/IE), Ifosfamide plus vincristine plus actinomycin D (IVA) or Ifosfamide plus vincristine plus Adriamycin (IVAd)\] is considered an appropriate treatment. 2. Minimum body weight of 15 kg 3. Life expectancy of at least 3 months with appropriate therapy 4. Female or male children and adolescents aged 2 to 17 years 5. Written informed consent provided by parent(s)/legal representative(s) of the pediatric patient and patient's assent if appropriate at the time of screening. 6. Fertile patients (male or female) must use highly reliable contraceptive measures. 7. Female patients who have attained menarche must have a negative urine pregnancy test at the screening visit. 8. White blood cell (WBC) count \>2.5\*10\^9/L, ANC ≥1.5\*10\^9/L, and platelet count ≥100\*10\^9/L (at screening and prior to chemotherapy)
Exclusion criteria
1. Primary myeloid disorders 2. Prior radiation therapy within 4 weeks of randomization into this study. 3. Previous exposure to filgrastim, pegfilgrastim, lenograstim or other G-CSF less than 6 months before randomization. 4. Known hypersensitivity to filgrastim, pegfilgrastim, lenograstim or any balugrastim excipients 5. Pregnancy or breastfeeding (if a patient becomes pregnant during the study she will be withdrawn from the study). 6. Major surgery, serious infection, within 3 weeks before first administration of study drug, serious trauma or compound medical procedure within the 4 weeks prior to the first study drug dose. 7. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical exams, ECG, laboratory tests or imaging.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC) of absolute neutrophil count (ANC) | Day 1 to 14 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to ANC nadir | Baseline to Week 16 | Time to ANC nadir, which is the time from the beginning of chemotherapy up to the occurrence of the ANC nadir |
| Time to ANC recovery | Baseline to Week 16 | Time to ANC recovery (ANC \>1.5\*10\^9/L) from nadir within each treatment cycle |
| Duration of severe neutropenia (DSN) | Baseline to Week 16 | Number of days subject experiences severe neutropenia (ANC \<0.5\*10\^9/L) |
| ANC nadir | Baseline to Week 16 | ANC nadir (measured in 10\^9/L), which is the lowest ANC recorded |
| Frequency of febrile neutropenia | Baseline to Week 16 | Frequency of febrile neutropenia (defined as body temperature \>38.5°C for more than one hour \[axillary measurement\] and ANC \<0.5\*10\^9/L) by cycle and across all cycles. |
| Summary of Participants with Adverse Events | From signing of informed consent to 16 weeks | — |
| Incidence of severe neutropenia | Baseline to Week 16 | Proportion of subjects who experience severe neutropenia (ANC \<0.5\*10\^9/L) |
Outcome results
None listed